Naldini
Diletta Naldini, Tavarnelle V.p. (fi) IT
Patent application number | Description | Published |
---|---|---|
20090156811 | Process for the Preparation of Bosentan - A process for the preparation of 4-tert-butyl-N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-[2,2′]bipyrimidinyl-4-yl]-benzenesulfonamide, bosentan, comprising the reaction of a compound of formula (II) or a salt thereof, | 06-18-2009 |
Luigi Naldini, Milan IT
Patent application number | Description | Published |
---|---|---|
20100041737 | Gene Vector - A gene vector comprising a miRNA sequence target. | 02-18-2010 |
20110218234 | GENE VECTOR FOR INDUCING TRANSGENE-SPECIFIC IMMUNE TOLERANCE - A gene vector adapted for transient expression of a transgene in a peripheral organ cell comprising a regulatory sequence operably linked to a transgene wherein the regulatory sequence prevents or reduces expression of said transgene in hematopoietic lineage cells. | 09-08-2011 |
20120128643 | GENE VECTOR - A gene vector for use in gene therapy comprising at least one miRNA sequence target operably linked to a nucleotide sequence having a corresponding miRNA in a hematopoietic progenitor cell (HSPC) or hematopoietic stem cell (HSC) which prevents or reduces expression of the nucleotide sequence in a HSPC or HSC but not in a differentiated cell. | 05-24-2012 |
20130143204 | DETERMINATION OF IN VIVO DNA DOUBLE-STRAND BREAK LOCALIZATION AND APPLICATION THEREOF - The present invention relates to a method for determining the in vivo localization of double-strand breaks in a host cell, comprising incubating a host cell suspected to comprise DNA double-strand breaks and a linear polynucleotide comprising a known sequence, detecting the in vivo insertion sites of said polynucleotide in the genome of said host cell, and assessing the in vivo localization of double-strand breaks. Further envisaged by the present invention is a method for obtaining an endonuclease with altered in vivo specificity. Finally, the present invention is directed to a kit for determining in vivo specificity of an endonuclease. | 06-06-2013 |
20140301990 | TARGETED DISRUPTION OF T CELL RECEPTOR GENES USING ENGINEERED ZINC FINGER PROTEIN NUCLEASES - Disclosed herein are methods and compositions for modifying TCR genes, using nucleases (zinc finger nucleases or TAL nucleases) to modify TCR genes. | 10-09-2014 |
Luigi Naldini, San Carlos, CA US
Patent application number | Description | Published |
---|---|---|
20080241929 | METHOD AND MEANS FOR PRODUCING HIGH TITER, SAFE, RECOMBINANT LENTIVIRUS VECTORS - Lentiviral vectors modified at the 5′ LTR or both the 5′ and 3′ LTR are useful in the production of recombinant lentivirus vectors (See the Figure). Such vectors can be produced in the absence of a functional tat gene. Multiple transformation of the host cell with the vector carrying the transgene enhances virus production. The vectors can contain inducible or conditional promoters. | 10-02-2008 |
20080286836 | METHOD AND MEANS FOR PRODUCING HIGH TITER, SAFE RECOMBINANT LENTIVIRUS VECTORS - Lentiviral vectors modified at the 5′ LTR or both the 5′ and 3′ LTR's are useful in the production of recombinant lentivirus vectors. Such vectors can be produced in the absence of a functional tat gene. Multiple transformation of the host cell with the vector carrying the transgene enhances virus production. | 11-20-2008 |
Luigi Naldini, Pioltello (mi) IT
Patent application number | Description | Published |
---|---|---|
20110158957 | Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases - Disclosed herein are methods and compositions for inactivating TCR genes, using zinc finger nucleases (ZFNs) comprising a zinc finger protein and a cleavage domain or cleavage half-domain in conditions able to preserve cell viability. Polynucleotides encoding ZFNs, vectors comprising polynucleotides encoding ZFNs and cells comprising polynucleotides encoding ZFNs and/or cells comprising ZFNs are also provided. Disclosed herein are also methods and compositions for expressing a functional exogenous TCR in the absence of endogenous TCR expression in T lymphocytes, including lymphocytes with a central memory phenotype. Polynucleotides encoding exogenous TCR, vectors comprising polynucleotides encoding exogenous TCR and cells comprising polynucleotides encoding exogenous TCR and/or cells comprising exogenous TCR are also provided. | 06-30-2011 |